Cargando…
ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG
BACKGROUND/PURPOSE: Phosphoglucomutase-1 deficiency is a subtype of congenital disorders of glycosylation (PGM1-CDG). Previous case-reports in PGM1-CDG patients receiving oral D-galactose (D-gal) showed clinical improvement. So far no systematic in vitro and clinical studies assessed safety and bene...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675745/ https://www.ncbi.nlm.nih.gov/pubmed/28617415 http://dx.doi.org/10.1038/gim.2017.41 |
_version_ | 1783276966222233600 |
---|---|
author | Wong, Sunnie Yan-Wai Gadomski, Therese van Scherpenzeel, Monique Honzik, Tomas Hansikova, Hana Brocke Holmefjord, Katja S. Mork, Marit Bowling, Francis Cegielska, Jolanta Sykut Koch, Dieter Hertecant, Jozef Preston, Graeme Jaeken, Jaak Peeters, Nicole Perez, Stefanie Nguyen, David Do Crivelly, Kea Emmerzaal, Tim Gibson, K. Michael Raymond, Kimiyo Bakar, Nurulamin Abu Foulquier, Francois Poschet, Gernot Ackermann, Amanda He, Miao Lefeber, Dirk Thiel, Christian Kozicz, Tamas Morava, Eva |
author_facet | Wong, Sunnie Yan-Wai Gadomski, Therese van Scherpenzeel, Monique Honzik, Tomas Hansikova, Hana Brocke Holmefjord, Katja S. Mork, Marit Bowling, Francis Cegielska, Jolanta Sykut Koch, Dieter Hertecant, Jozef Preston, Graeme Jaeken, Jaak Peeters, Nicole Perez, Stefanie Nguyen, David Do Crivelly, Kea Emmerzaal, Tim Gibson, K. Michael Raymond, Kimiyo Bakar, Nurulamin Abu Foulquier, Francois Poschet, Gernot Ackermann, Amanda He, Miao Lefeber, Dirk Thiel, Christian Kozicz, Tamas Morava, Eva |
author_sort | Wong, Sunnie Yan-Wai |
collection | PubMed |
description | BACKGROUND/PURPOSE: Phosphoglucomutase-1 deficiency is a subtype of congenital disorders of glycosylation (PGM1-CDG). Previous case-reports in PGM1-CDG patients receiving oral D-galactose (D-gal) showed clinical improvement. So far no systematic in vitro and clinical studies assessed safety and benefits of D-gal supplementation. In a prospective pilot study, we evaluated the effects of oral D-gal in nine patients. METHODS/RESULTS: D-gal supplementation was increased to 1.5 g/kg/day (maximum 50 g/day) in three increments over 18 weeks. Laboratory studies were performed before and during treatment to monitor safety and effect on serum transferrin-glycosylation, coagulation, liver and endocrine function. Additionally, the effect of D-gal on cellular glycosylation was characterized in vitro. Eight patients were compliant with D-gal supplementation. No adverse effects were reported. Abnormal baseline results (ALT/AST/aPTT) improved or normalized already using 1g/kg/day D-gal. Antithrombin-III levels and Transferrin-glycosylation showed significant improvement, and increase in galactosylation and whole glycan content. In vitro studies before treatment showed N-glycan hyposialylation, altered O-linked glycans, abnormal LLO-profile, and abnormal nucleotide-sugars in patient fibroblasts. Most cellular abnormalities improved or normalized following D-gal treatment. CONCLUSION: D-gal increased both UDP-Glc and UDP-gal levels and improved LLO fractions in concert with improved glycosylation in PGM1-CDG. Oral D-gal supplementation is a safe and effective treatment for PGM1-CDG in this pilot study. Transferrin glycosylation and ATIII levels were useful trial end points. Larger, longer duration trials are ongoing. |
format | Online Article Text |
id | pubmed-5675745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-56757452017-12-15 ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG Wong, Sunnie Yan-Wai Gadomski, Therese van Scherpenzeel, Monique Honzik, Tomas Hansikova, Hana Brocke Holmefjord, Katja S. Mork, Marit Bowling, Francis Cegielska, Jolanta Sykut Koch, Dieter Hertecant, Jozef Preston, Graeme Jaeken, Jaak Peeters, Nicole Perez, Stefanie Nguyen, David Do Crivelly, Kea Emmerzaal, Tim Gibson, K. Michael Raymond, Kimiyo Bakar, Nurulamin Abu Foulquier, Francois Poschet, Gernot Ackermann, Amanda He, Miao Lefeber, Dirk Thiel, Christian Kozicz, Tamas Morava, Eva Genet Med Article BACKGROUND/PURPOSE: Phosphoglucomutase-1 deficiency is a subtype of congenital disorders of glycosylation (PGM1-CDG). Previous case-reports in PGM1-CDG patients receiving oral D-galactose (D-gal) showed clinical improvement. So far no systematic in vitro and clinical studies assessed safety and benefits of D-gal supplementation. In a prospective pilot study, we evaluated the effects of oral D-gal in nine patients. METHODS/RESULTS: D-gal supplementation was increased to 1.5 g/kg/day (maximum 50 g/day) in three increments over 18 weeks. Laboratory studies were performed before and during treatment to monitor safety and effect on serum transferrin-glycosylation, coagulation, liver and endocrine function. Additionally, the effect of D-gal on cellular glycosylation was characterized in vitro. Eight patients were compliant with D-gal supplementation. No adverse effects were reported. Abnormal baseline results (ALT/AST/aPTT) improved or normalized already using 1g/kg/day D-gal. Antithrombin-III levels and Transferrin-glycosylation showed significant improvement, and increase in galactosylation and whole glycan content. In vitro studies before treatment showed N-glycan hyposialylation, altered O-linked glycans, abnormal LLO-profile, and abnormal nucleotide-sugars in patient fibroblasts. Most cellular abnormalities improved or normalized following D-gal treatment. CONCLUSION: D-gal increased both UDP-Glc and UDP-gal levels and improved LLO fractions in concert with improved glycosylation in PGM1-CDG. Oral D-gal supplementation is a safe and effective treatment for PGM1-CDG in this pilot study. Transferrin glycosylation and ATIII levels were useful trial end points. Larger, longer duration trials are ongoing. 2017-06-15 2017-11 /pmc/articles/PMC5675745/ /pubmed/28617415 http://dx.doi.org/10.1038/gim.2017.41 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Wong, Sunnie Yan-Wai Gadomski, Therese van Scherpenzeel, Monique Honzik, Tomas Hansikova, Hana Brocke Holmefjord, Katja S. Mork, Marit Bowling, Francis Cegielska, Jolanta Sykut Koch, Dieter Hertecant, Jozef Preston, Graeme Jaeken, Jaak Peeters, Nicole Perez, Stefanie Nguyen, David Do Crivelly, Kea Emmerzaal, Tim Gibson, K. Michael Raymond, Kimiyo Bakar, Nurulamin Abu Foulquier, Francois Poschet, Gernot Ackermann, Amanda He, Miao Lefeber, Dirk Thiel, Christian Kozicz, Tamas Morava, Eva ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG |
title | ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG |
title_full | ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG |
title_fullStr | ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG |
title_full_unstemmed | ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG |
title_short | ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG |
title_sort | oral d-galactose supplementation in pgm1-cdg |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675745/ https://www.ncbi.nlm.nih.gov/pubmed/28617415 http://dx.doi.org/10.1038/gim.2017.41 |
work_keys_str_mv | AT wongsunnieyanwai oraldgalactosesupplementationinpgm1cdg AT gadomskitherese oraldgalactosesupplementationinpgm1cdg AT vanscherpenzeelmonique oraldgalactosesupplementationinpgm1cdg AT honziktomas oraldgalactosesupplementationinpgm1cdg AT hansikovahana oraldgalactosesupplementationinpgm1cdg AT brockeholmefjordkatjas oraldgalactosesupplementationinpgm1cdg AT morkmarit oraldgalactosesupplementationinpgm1cdg AT bowlingfrancis oraldgalactosesupplementationinpgm1cdg AT cegielskajolantasykut oraldgalactosesupplementationinpgm1cdg AT kochdieter oraldgalactosesupplementationinpgm1cdg AT hertecantjozef oraldgalactosesupplementationinpgm1cdg AT prestongraeme oraldgalactosesupplementationinpgm1cdg AT jaekenjaak oraldgalactosesupplementationinpgm1cdg AT peetersnicole oraldgalactosesupplementationinpgm1cdg AT perezstefanie oraldgalactosesupplementationinpgm1cdg AT nguyendaviddo oraldgalactosesupplementationinpgm1cdg AT crivellykea oraldgalactosesupplementationinpgm1cdg AT emmerzaaltim oraldgalactosesupplementationinpgm1cdg AT gibsonkmichael oraldgalactosesupplementationinpgm1cdg AT raymondkimiyo oraldgalactosesupplementationinpgm1cdg AT bakarnurulaminabu oraldgalactosesupplementationinpgm1cdg AT foulquierfrancois oraldgalactosesupplementationinpgm1cdg AT poschetgernot oraldgalactosesupplementationinpgm1cdg AT ackermannamanda oraldgalactosesupplementationinpgm1cdg AT hemiao oraldgalactosesupplementationinpgm1cdg AT lefeberdirk oraldgalactosesupplementationinpgm1cdg AT thielchristian oraldgalactosesupplementationinpgm1cdg AT kozicztamas oraldgalactosesupplementationinpgm1cdg AT moravaeva oraldgalactosesupplementationinpgm1cdg |